JSJohanna S. Salzer

Johanna S. Salzer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Johanna S. Salzer has a total of 93 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Low healthcare provider knowledge of ehrlichiosis and other tickborne diseases - United States, 2024

    by Sydney N. Adams, Marissa L. Taylor, David W. McCormick, Emma S. Jones, Gilbert J. Kersh, Alexandra L. Premkumar, Johanna S. Salzer


  • Open Access

    Public awareness of alpha-gal syndrome and tick bite prevention practices, United States, Fall 2023

    by Marissa Taylor, Emma Jones, Alexandra L. Premkumar, Amy E. Lockwood, Lacey A. Stone, Johanna S. Salzer

    Alpha-gal syndrome (AGS) is an emerging non-infectious tickborne disease that can cause severe allergic symptoms and be challenging for patients to manage. We sought to understand public awareness of AGS, especially relative to other tickborne diseases. We used a 2023 nationally representative survey of adults to investigate public awareness of AGS in the United States and found that knowledge was very low, with 70% of respondents having no prior knowledge of AGS. Respondents with prior AGS knowledge were more concerned about both AGS and infectious tickborne diseases, including Lyme disease, than those without prior AGS knowledge. This study suggests that improving public awareness of AGS could encourage individuals to try to prevent tick bites.

  • Open Access

    A mutation associated with resistance to synthetic pyrethroids is widespread in US populations of the tropical lineage of Rhipicephalus sanguineus s.l

    by Nathan E. Stone, Rebecca Ballard, Reanna M. Bourgeois, Grant L. Pemberton, Ryelan F. McDonough, Megan C. Ruby, Laura H. Backus, Andrés M. López-Pérez, Darrin Lemmer, Zane Koch, et al.


  • Open Access

    Assessing rodents as carriers of pathogenic Leptospira species in the U.S. Virgin Islands and their risk to animal and public health

    by Camila Hamond, A. Springer Browne, Leah H. de Wilde, Richard L. Hornsby, Karen LeCount, Tammy Anderson, Tod Stuber, Hannah M. Cranford, Stephanie K. Browne, Gerard Blanchard, et al.

    Leptospirosis is a global zoonotic disease caused by pathogenic bacteria of the genus Leptospira. We sought to determine if rodents in U.S. Virgin Islands (USVI) are carriers of Leptospira. In total, 140 rodents were sampled, including 112 Mus musculus and 28 Rattus rattus. A positive carrier status was identified for 64/140 (45.7%); 49 (35.0%) were positive by dark-field microscopy, 60 (42.9%) by culture, 63 (45.0%) by fluorescent antibody testing, and 61 (43.6%) by real-time polymerase chain reaction (rtPCR). Molecular typing indicated that 48 isolates were L. borgpetersenii and 3 were L. kirschneri; the remaining nine comprised mixed species. In the single culture-negative sample that was rtPCR positive, genotyping directly from the kidney identified L. interrogans. Serotyping of L. borgpetersenii isolates identified serogroup Ballum and L. kirschneri isolates as serogroup Icterohaemorrhagiae. These results demonstrate that rodents are significant Leptospira carriers and adds to understanding the ecoepidemiology of leptospirosis in USVI.


  • Open Access

    Mongooses (Urva auropunctata) as reservoir hosts of Leptospira species in the United States Virgin Islands, 2019–2020

    by Hannah M. Cranford, A. Springer Browne, Karen LeCount, Tammy Anderson, Camila Hamond, Linda Schlater, Tod Stuber, Valicia J. Burke-France, Marissa Taylor, Cosme J. Harrison, et al.

    During 2019–2020, the Virgin Islands Department of Health investigated potential animal reservoirs of Leptospira spp., the bacteria that cause leptospirosis. In this cross-sectional study, we investigated Leptospira spp. exposure and carriage in the small Indian mongoose (Urva auropunctata, syn: Herpestes auropunctatus), an invasive animal species. This study was conducted across the three main islands of the U.S. Virgin Islands (USVI), which are St. Croix, St. Thomas, and St. John. We used the microscopic agglutination test (MAT), fluorescent antibody test (FAT), real-time polymerase chain reaction (lipl32 rt-PCR), and bacterial culture to evaluate serum and kidney specimens and compared the sensitivity, specificity, positive predictive value, and negative predictive value of these laboratory methods. Mongooses (n = 274) were live-trapped at 31 field sites in ten regions across USVI and humanely euthanized for Leptospira spp. testing. Bacterial isolates were sequenced and evaluated for species and phylogenetic analysis using the ppk gene. Anti-Leptospira spp. antibodies were detected in 34% (87/256) of mongooses. Reactions were observed with the following serogroups: Sejroe, Icterohaemorrhagiae, Pyrogenes, Mini, Cynopteri, Australis, Hebdomadis, Autumnalis, Mankarso, Pomona, and Ballum. Of the kidney specimens examined, 5.8% (16/270) were FAT-positive, 10% (27/274) were culture-positive, and 12.4% (34/274) were positive by rt-PCR. Of the Leptospira spp. isolated from mongooses, 25 were L. borgpetersenii, one was L. interrogans, and one was L. kirschneri. Positive predictive values of FAT and rt-PCR testing for predicting successful isolation of Leptospira by culture were 88% and 65%, respectively. The isolation and identification of Leptospira spp. in mongooses highlights the potential role of mongooses as a wildlife reservoir of leptospirosis; mongooses could be a source of Leptospira spp. infections for other wildlife, domestic animals, and humans. Leptospirosis is a zoonotic disease caused by bacteria of the genus Leptospira. To better understand local reservoirs and risk factors to humans and animals, during 2019–2020, the Virgin Islands Department of Health (VIDOH) investigated Leptospira spp. in association with the small Indian mongoose (Urva auropunctata, syn: Herpestes auropunctatus) across the three main islands of the United States Virgin Islands (USVI) (St. Croix, St. Thomas, and St. John). Mongoose blood and kidney samples were evaluated by laboratory testing: microscopic agglutination test, fluorescent antibody test (FAT), real-time polymerase chain reaction (lipl32 rt-PCR), and culture. Of 256 mongooses, 34% were exposed to Leptospira spp. To assess active infection in mongooses, kidney samples were examined resulting 5.8% (16/270) FAT-positive, 10% (27/274) culture-positive, and 12.4% (34/274) rt-PCR-positive. Validity was compared between test types showing higher positive predictive value for FAT and rt-PCR testing for predicting successful culture, the reference standard for diagnosis. Through the detection and isolation of Leptospira spp. in mongooses across the USVI, we identified mongooses as potential disease vectors to the local population and added to the limited data for the Caribbean region. Furthermore, a validity assessment of reference testing provides data to potentially inform future leptospirosis diagnostics.


  • Open Access

    Teaching a new mouse old tricks: Humanized mice as an infection model for Variola virus

    by Christina L. Hutson, Ashley V. Kondas, Jana M. Ritter, Zachary Reed, Sharon Dietz Ostergaard, Clint N. Morgan, Nadia Gallardo-Romero, Cassandra Tansey, Matthew R. Mauldin, Johanna S. Salzer, et al.

    Smallpox, caused by the solely human pathogen Variola virus (VARV), was declared eradicated in 1980. While known VARV stocks are secure, smallpox remains a bioterrorist threat agent. Recent U.S. Food and Drug Administration approval of the first smallpox anti-viral (tecovirimat) therapeutic was a successful step forward in smallpox preparedness; however, orthopoxviruses can become resistant to treatment, suggesting a multi-therapeutic approach is necessary. Animal models are required for testing medical countermeasures (MCMs) and ideally MCMs are tested directly against the pathogen of interest. Since VARV only infects humans, a representative animal model for testing therapeutics directly against VARV remains a challenge. Here we show that three different humanized mice strains are highly susceptible to VARV infection, establishing the first small animal model using VARV. In comparison, the non-humanized, immunosuppressed background mouse was not susceptible to systemic VARV infection. Following an intranasal VARV challenge that mimics the natural route for human smallpox transmission, the virus spread systemically within the humanized mouse before mortality (~ 13 days post infection), similar to the time from exposure to symptom onset for ordinary human smallpox. Our identification of a permissive/representative VARV animal model can facilitate testing of MCMs in a manner consistent with their intended use. Preparedness activities against highly transmissible respiratory viruses with high mortality have been highlighted during the ongoing COVID-19 pandemic. Smallpox, caused by Variola virus (VARV) infection, is highly transmissible and estimated to have killed 300 million people in the 20th century alone with ~30% mortality. Through an intensive vaccination campaign smallpox was declared eradicated in 1980 and routine smallpox vaccination of individuals ceased. Today’s population has little/no immunity against VARV; if smallpox were to re-emerge the worldwide results would be devastating. Development of antiviral strategies is critical for outbreak response efforts and in order to truly gauge the potential effectiveness of a medical countermeasure (MCM), it must be tested directly against the pathogen. VARV is solely a human pathogen and infections of surrogate animal models have been largely unsuccessful. Here we use the humanized mouse to establish the first small animal model using VARV. We found that the virus spread systemically within humanized mice before mortality (~ 13 days post infection), similar to the time from exposure to symptom onset for ordinary human smallpox. These findings improve upon current MCM efficacy testing methods by providing a means to conduct in vivo evaluations of smallpox MCMs directly against VARV.


  • Open Access

    Impact of Anthropogenic Disturbance on Native and Invasive Trypanosomes of Rodents in Forested Uganda

    by Johanna S. Salzer, C. Miguel Pinto, Dylan C. Grippi, Amanda Jo Williams-Newkirk, Julian Kerbis Peterhans, Innocent B. Rwego, Darin S. Carroll, Thomas R. Gillespie

    Habitat disturbance and anthropogenic change are globally associated with extinctions and invasive species introductions. Less understood is the impact of environmental change on the parasites harbored by endangered, extinct, and introduced species. To improve our understanding of the impacts of anthropogenic disturbance on such host–parasite interactions, we investigated an invasive trypanosome (Trypanosoma lewisi). We screened 348 individual small mammals, representing 26 species, from both forested and non-forested habitats in rural Uganda. Using microscopy and PCR, we identified 18% of individuals (order Rodentia) as positive for trypanosomes. Further phylogenetic analyses revealed two trypanosomes circulating—T. lewisi and T. varani. T. lewisi was found in seven species both native and invasive, while T. varani was identified in only three native forest species. The lack of T. varani in non-forested habitats suggests that it is a natural parasite of forest-dwelling rodents. Our findings suggest that anthropogenic disturbance may lead to spillover of an invasive parasite (T. lewisi) from non-native to native species, and lead to local co-extinction of a native parasite (T. varani) and native forest-dwelling hosts.